Publications by authors named "Brenda Moreira-Walsh"
Being introduced in 2010, fingolimod was among the first oral therapies for relapsing multiple sclerosis (MS). Since that time, postmarketing surveillance has noted several case reports of various cryptococcal infections associated with fingolimod use. To date, approximately 15 such case reports have been published.
View Article and Find Full Text PDFThe fungal pathogen Cryptococcus neoformans causes up to 278 000 infections each year globally, resulting in up to 180,000 deaths annually, mostly impacting immunocompromised people. Therapeutic options for C. neoformans infections are very limited.
View Article and Find Full Text PDFArticle Synopsis
- Opportunistic fungal infections significantly impact immunocompromised patients, highlighting the need for more effective antifungal therapies due to limited existing options.
- Ciclopirox olamine, a known antifungal, has led to the synthesis of ten new -hydroxypyridone derivatives to explore their potential for systemic use against various fungal species.
- Eight of the derivatives demonstrated antifungal activity at low concentrations while showing synergies with other antifungals, indicating promising starting points for developing improved treatments targeting these infections.